JP5313926B2 - 皮膚用エマルジョンおよびその製造方法 - Google Patents
皮膚用エマルジョンおよびその製造方法 Download PDFInfo
- Publication number
- JP5313926B2 JP5313926B2 JP2009546767A JP2009546767A JP5313926B2 JP 5313926 B2 JP5313926 B2 JP 5313926B2 JP 2009546767 A JP2009546767 A JP 2009546767A JP 2009546767 A JP2009546767 A JP 2009546767A JP 5313926 B2 JP5313926 B2 JP 5313926B2
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- alkyl
- composition
- surfactant
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000839 emulsion Substances 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 claims abstract description 122
- 239000004094 surface-active agent Substances 0.000 claims abstract description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 37
- 239000012071 phase Substances 0.000 claims abstract description 29
- 239000008346 aqueous phase Substances 0.000 claims abstract description 17
- 239000004530 micro-emulsion Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000004088 foaming agent Substances 0.000 claims abstract description 8
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 7
- 239000002562 thickening agent Substances 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 5
- 238000004090 dissolution Methods 0.000 claims abstract description 4
- 238000010907 mechanical stirring Methods 0.000 claims abstract description 4
- 239000003945 anionic surfactant Substances 0.000 claims abstract description 3
- -1 alkyl glucosides Chemical class 0.000 claims description 41
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 210000004761 scalp Anatomy 0.000 claims description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 229930182478 glucoside Natural products 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 208000017520 skin disease Diseases 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 9
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 230000000087 stabilizing effect Effects 0.000 claims description 8
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 239000004064 cosurfactant Substances 0.000 claims description 6
- 239000003974 emollient agent Substances 0.000 claims description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 5
- 229960004311 betamethasone valerate Drugs 0.000 claims description 5
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 4
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 claims description 4
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims description 4
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 229940073499 decyl glucoside Drugs 0.000 claims description 4
- 150000008131 glucosides Chemical class 0.000 claims description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003929 acidic solution Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000003637 basic solution Substances 0.000 claims description 3
- 229960004703 clobetasol propionate Drugs 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 3
- 229960004125 ketoconazole Drugs 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 229940070710 valerate Drugs 0.000 claims description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 3
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical group C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims description 2
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 claims description 2
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 claims description 2
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical group [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 2
- VKELSQNRSVJHGR-UHFFFAOYSA-N 4-oxo-4-sulfooxybutanoic acid Chemical compound OC(=O)CCC(=O)OS(O)(=O)=O VKELSQNRSVJHGR-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims description 2
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- 229920002367 Polyisobutene Polymers 0.000 claims description 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- DERCOWNWEPPIHD-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2O DERCOWNWEPPIHD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 claims description 2
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims description 2
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229960003204 amorolfine Drugs 0.000 claims description 2
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 2
- 229960000870 betamethasone benzoate Drugs 0.000 claims description 2
- SOQJPQZCPBDOMF-YCUXZELOSA-N betamethasone benzoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@@H]1C)C(=O)CO)C(=O)C1=CC=CC=C1 SOQJPQZCPBDOMF-YCUXZELOSA-N 0.000 claims description 2
- 229960001102 betamethasone dipropionate Drugs 0.000 claims description 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims description 2
- 229960002206 bifonazole Drugs 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 235000010338 boric acid Nutrition 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 229960002242 chlorocresol Drugs 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 238000010924 continuous production Methods 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 claims description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 229960001274 fenticonazole Drugs 0.000 claims description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 2
- 229960000785 fluocinonide Drugs 0.000 claims description 2
- 229950008509 fluocortin butyl Drugs 0.000 claims description 2
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 claims description 2
- 229960001048 fluorometholone Drugs 0.000 claims description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 229960002383 halcinonide Drugs 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 claims description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- ATYGMDZIBQHJFX-UHFFFAOYSA-N imidazolidine;urea Chemical class NC(N)=O.C1CNCN1 ATYGMDZIBQHJFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004849 isoconazole Drugs 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 229960002744 mometasone furoate Drugs 0.000 claims description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 2
- 150000002780 morpholines Chemical class 0.000 claims description 2
- 229940105132 myristate Drugs 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229960004031 omoconazole Drugs 0.000 claims description 2
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 claims description 2
- 229960003483 oxiconazole Drugs 0.000 claims description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 239000010690 paraffinic oil Substances 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229920001083 polybutene Polymers 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical group [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 claims description 2
- 229960005265 selenium sulfide Drugs 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000001587 sorbitan monostearate Substances 0.000 claims description 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 229960002607 sulconazole Drugs 0.000 claims description 2
- 229960002722 terbinafine Drugs 0.000 claims description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 229960004880 tolnaftate Drugs 0.000 claims description 2
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000004711 α-olefin Substances 0.000 claims description 2
- 239000012744 reinforcing agent Substances 0.000 claims 3
- 239000004872 foam stabilizing agent Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 235000021317 phosphate Nutrition 0.000 claims 2
- 159000000000 sodium salts Chemical group 0.000 claims 2
- PAEMERHSTIDLSE-QMCAAQAGSA-N (2r,3r,4s,5s,6r)-2-hexadecoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PAEMERHSTIDLSE-QMCAAQAGSA-N 0.000 claims 1
- UFSKIYBOKFBSOA-MLYSRARTSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octadecoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UFSKIYBOKFBSOA-MLYSRARTSA-N 0.000 claims 1
- ORUDEUCNYHCHPB-OUUBHVDSSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-tetradecoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ORUDEUCNYHCHPB-OUUBHVDSSA-N 0.000 claims 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical group NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000003470 adrenal cortex hormone Substances 0.000 claims 1
- 150000001414 amino alcohols Chemical class 0.000 claims 1
- 229960004365 benzoic acid Drugs 0.000 claims 1
- 229960002645 boric acid Drugs 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 229960004375 ciclopirox olamine Drugs 0.000 claims 1
- 229960002842 clobetasol Drugs 0.000 claims 1
- FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 claims 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims 1
- 229960003662 desonide Drugs 0.000 claims 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims 1
- 150000002193 fatty amides Chemical class 0.000 claims 1
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 claims 1
- 229940042902 flumethasone pivalate Drugs 0.000 claims 1
- 229960000631 hydrocortisone valerate Drugs 0.000 claims 1
- 229960000448 lactic acid Drugs 0.000 claims 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 claims 1
- 229940048848 lauryl glucoside Drugs 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 abstract description 5
- 238000005187 foaming Methods 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000003019 stabilising effect Effects 0.000 abstract 1
- 239000006260 foam Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- 239000002453 shampoo Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 8
- 230000035515 penetration Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036620 skin dryness Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000011269 tar Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940043810 zinc pyrithione Drugs 0.000 description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FPUCFPHVHZDZRC-UHFFFAOYSA-N OS(O)=O.[SeH2] Chemical compound OS(O)=O.[SeH2] FPUCFPHVHZDZRC-UHFFFAOYSA-N 0.000 description 1
- 241000765083 Ondina Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/596—Mixtures of surface active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
−少なくとも1種の非イオン性エトキシル化界面活性剤;
−非イオン性エトキシル化界面活性剤を安定化させる少なくとも1種の共界面活性剤;
−少なくとも1種の非イオン性親水性非エトキシル化界面活性剤;
−アニオン性界面活性剤の群から選択される少なくとも1種の起泡剤;
からなる界面活性剤の系を含んでなることを特徴とする。
−脂肪相を界面活性剤系と混合して、機械的攪拌により混合物を均質化し;
−例えば増粘剤のような異なる補助剤を水相で混合し;
−組成物の透明性を得られる速度で十分な時間にわたり、攪拌しながら水相を脂肪相へ配合し;
−必要に応じて、酸または塩基性溶液を加えることにより、エマルジョンのpHを調整し;
−室温で活性成分の完全溶解まで攪拌することにより、活性成分を配合する;
ことを含んでなる、本発明による組成物の製造方法である。
成分:
− Texapon N 70RおよびTexapon NSORナトリウムラウレスサルフェートをCognisから得た。
− Ondina 68RおよびPrimol 352R鉱油をShellおよびExxon Mobilから各々得た。
− PEG−40 LabrasolR水素化ヒマシ油をGatterfosseから得た。
− MEA Comperlan KDRコカミドをCognisから得た。
− Oramix NS 10RデシルグルコシドをSeppicから得た。
− オレイックプルロール(oleic plurol)およびジイソステアリックプルロール(diisostearic plurol)をGatterfosseから得た。
いかなる活性成分もない2種のマイクロエマルジョン(ベース)を製造および解析した。それらの組成が表1で示され、それらの解析結果が表2でまとめられている。パーセンテージは水中の溶液における対応品の重量で濃度を示している。
活性成分を含んでなる2種のマイクロエマルジョンを製造した。粘度はベースの場合と比較して改善されたが、但しNaCl含有率を増加させる。Texapon NSOをTexapon N70で置き換え、pHを乳酸で調整した。処方が表3で示されている。
Claims (38)
- 水相に分散された微小滴の脂肪相および皮膚用活性成分を含んでなる、安定な水中油型マイクロエマルジョンとしてのフォーミングゲル化組成物であって、
−少なくとも1種の非イオン性エトキシル化界面活性剤;
−飽和または不飽和脂肪酸の、グリセロールの、ポリグリセロールの、プロピレングリコールの、グリコールの、ポリエチレングリコールの、および、ソルビタンの非エトキシル化エステル、並びにトリグリセロールジイソステアレート、トリグリセロールオレエート、プロピレングリコールモノラウレート、プロピレングリコールモノカプリレート、および、ソルビタンモノステアレートからなる群より選択される非イオン性エトキシル化界面活性剤を安定化させる少なくとも1種の共界面活性剤;
−糖誘導体、アルキルグルコシド、1〜7のグルコース単位を含んでなるC 8 −C 22 アルキルポリグルコシド、オクチルグルコシド、デシルグルコシド、ラウリルグルコシド、ミリスチルグルコシド、パルミチルグルコシド、ステアリルグルコシド、オレイルグルコシド、ベヘニルグルコシド、1〜3のグルコース単位を含んでなるC 10 −C 14 グルコシド誘導体、デシルグルコシドからなる群より選択され、かつ総重量の1〜30%の、少なくとも1種の非イオン性親水性非エトキシル化界面活性剤;
−アニオン性界面活性剤の群から選択され、総重量の15〜25%の、少なくとも1種の起泡剤;および
−総重量の1〜3%の増粘剤
からなる界面活性剤系を含んでなり、かつ、
非イオン性エトキシル化界面活性剤および非イオン性エトキシル化界面活性剤を安定化する共界面活性剤の総量が重量で、総重量の15〜40%であることを特徴とする、組成物。 - 活性成分が、皮膚および/または頭皮の皮膚疾患へ向けた治療効力を発揮する、請求項1に記載の組成物。
- 活性成分が、脂肪相に溶解されている、請求項1または2に記載の組成物。
- 活性成分が、ジプロピオン酸アルクロメタゾン、アムシノニド、ジプロピオン酸ベクロメタゾン、安息香酸ベタメタゾン、吉草酸ベタメタゾン、ジプロピオン酸ベタメタゾン、ブデソニド、プロピオン酸クロベタゾール、17−プロピオン酸クロベタゾール、酪酸クロベタゾール、デソニド、デスオキシメタゾン、デキサメタゾン、二酢酸デジフロラゾン、吉草酸ジフルコルトロン、フルランドレノロン、酢酸フルプレドニデン、フルオコルトロン、フルオコルチンブチル、フルオシノニド、フルオシノロンアセトニド、フルクロロロンアセトニド、ピバル酸フルメタゾン、塩酸フュージリン、フルメトロン、ハルシノニド、ヒドロコルチゾン、酢酸ヒドロコルチゾン、酪酸ヒドロコルチゾン、吉草酸ヒドロコルチゾン、酢酸メチルプレドニゾロン、フロ酸モメタゾン、メチルプレドニゾロン、プレドニゾロン、トリアムシノロンアセトニドからなる群より選択されるコルチコイド、またはその製薬上許容される混合物から選択されるコルチコイドである、請求項1〜3のいずれか一項に記載の組成物。
- 活性成分が、イミダゾール類、非イミダゾール化ピリドン類、モルホリン類、アリルアミン類からなる群より選択される抗真菌剤である、請求項1〜3のいずれか一項に記載の組成物。
- イミダゾールが、ケトコナゾール、ビホナゾール、クロトリマゾール、エコナゾール、フェンチコナゾール、イソコナゾール、ミコナゾール、オモコナゾール、オキシコナゾール、スルコナゾール、チオコナゾールからなる群より選択される、請求項5に記載の組成物。
- 非イミダゾール化ピリドンがシクロピロクスオラミンである、請求項5に記載の組成物。
- モルホリンがアモロルフィンである、請求項5に記載の組成物。
- アリルアミンが、テルビナフィンおよびトルナフテートからなる群より選択される、請求項5に記載の組成物。
- 活性成分が抗脂漏剤である、請求項1〜3のいずれか一項に記載の組成物。
- 抗脂漏剤が、硫化セレンまたは過酸化ベンゾイルである、請求項10に記載の組成物。
- 皮膚用活性成分の量が、重量で、総量の0.001%〜5%である、請求項1〜11のいずれか一項に記載の組成物。
- 水相が、グリセロール、プロピレングリコール、ソルビトール、エタノールからなる群より選択される1種以上の化粧品上許容される溶媒を更に含んでなる、請求項1〜12のいずれか一項に記載の組成物。
- 水相が、酸、塩基、着色剤、保湿剤、緩和剤、回復剤、剥離剤、酸化防止活性剤からなる群より選択される1種以上の水溶性化合物を更に含んでなる、請求項1〜13のいずれか一項に記載の組成物。
- 水相の量が、重量で、総量の30%〜60%である、請求項1〜14のいずれか一項に記載の組成物。
- 脂肪相の量が、重量で、総量の0.5%〜20%である、請求項1〜15のいずれか一項に記載の組成物。
- 脂肪相が、単独または混合物で用いられる、水素化されたまたは水素化されていない、合成または合成でない、飽和または不飽和の、植物または鉱油、トリグリセリド、モノグリセリド、ジグリセリド、脂肪酸誘導体、脂肪酸エステル、天然炭化水素、環状または脂肪族、線状または分岐油、揮発性または非揮発性の、有機変性されたまたはそうでない、可溶性またはそうでないシリコーン、過フッ素化またはフッ素化油、ポリブテンおよびポリイソブテン、液体脂肪酸、パラフィン系油、オクトドデシルミリステート、イソプロピルミリステート、トリカプリル酸グリセロール、カプリン−カプリル酸グリセリドからなる群より選択される成分を含んでなる、請求項1〜16のいずれか一項に記載の組成物。
- 非イオン性エトキシル化界面活性剤が、エトキシル化脂肪アルコール、エトキシル化脂肪酸、アルキルまたはアルケニル基でエーテル化されたエトキシル化脂肪酸、アルキルまたはアルケニル基でエステル化されたエトキシル化脂肪酸、飽和または不飽和脂肪酸の、グリセロールの、プロピレングリコールの、グリコールの、ポリエチレングリコールの、ソルビタンのエトキシル化エステル、グリセリドとポリエチレングリコールのカプリル酸エステルの混合物、エチレンオキシドとプロピレンのコポリマーからなる群より選択される、請求項1〜17のいずれか一項に記載の組成物。
- 組成物に存在する非イオン性エトキシル化界面活性剤の重量による量が、組成物の総量の20%以下である、請求項1〜18のいずれか一項に記載の組成物。
- 非イオン性エトキシル化界面活性剤を安定化させる共界面活性剤の重量による量対非イオン性エトキシル化界面活性剤の量の比率が、1:2〜1:6である、請求項1〜19のいずれか一項に記載の組成物。
- 非イオン性エトキシル化界面活性剤および非イオン性エトキシル化界面活性剤を安定化させる共界面活性剤の重量による総量が、重量で、総量の20%〜35%である、請求項1〜20のいずれか一項に記載の組成物。
- 非エトキシル化親水性非イオン性界面活性剤の重量による量が、総量の1〜30%である、請求項1〜21のいずれか一項に記載の組成物。
- pHが3〜8である、請求項1〜22のいずれか一項に記載の組成物。
- pHが乳酸を加えることで調整される、請求項1〜23のいずれか一項に記載の組成物。
- アニオン性起泡剤が、アルキルサルフェート、アルキルエーテルサルフェート、アルキルアミドエーテルサルフェート、アルキルアリールポリエーテルサルフェート、アルキルモノグリセリドサルフェート、アルキルモノグリセリドエーテルサルフェート、アルキルモノグリセリドスルホネート、アルキルスルホネート、アルキルホスフェート、アルキルイセチオネート、アルキルカルボキシレート、アルキルエーテルカルボキシレート、アルキルエーテルアミドカルボキシレート、アルキルアミドスルホネート、アルキルアリールスルホネート、α−オレフィンスルホネート、パラフィンスルホネート、アルキルスルホサクシネート、アルキルエーテルスルホサクシネート、アルキルアミドスルホサクシネート、アルキルスルホサクシナメート、アルキルスルホアセテート、アルキルエーテルホスフェート、アシルサルコシネート、N−アシルアミノ酸、アシルイセチオネートおよびN−アシルタウレートのナトリウム、アンモニウム、アミン、アミノアルコールまたはマグネシウム塩からなる群より選択される、請求項1〜24のいずれか一項に記載の組成物。
- 少なくとも1種の泡安定化または強化剤を更に含んでなる、請求項1〜25のいずれか一項に記載の組成物。
- 安定化または強化剤が、脂肪酸アミド、アルキルアミド、モノおよびジエタノールアミド、脂肪酸イソプロパノールアミドからなる群より選択される、請求項26に記載の組成物。
- 泡安定化または強化剤の重量による量が、総量の0%〜10%である、請求項26または27に記載の組成物。
- 増粘剤が、非架橋剤から選択される、請求項1〜28のいずれか一項に記載の組成物。
- 増粘剤がナトリウム塩、カルボマーまたはキサンタンガムからなる群より選択される、請求項29に記載の組成物。
- ナトリウム塩が、塩化ナトリウムまたはクエン酸ナトリウムである、請求項30に記載の組成物。
- 保存剤を更に含んでなる、請求項1〜31のいずれか一項に記載の組成物。
- 保存剤がホウ酸、安息香酸、乳酸、ソルビン酸、ベンジルアルコール、フェノキシエタノール、クロロクレゾール、パラヒドロキシ安息香酸のエステル、イミダゾリジン尿素の誘導体からなる群より選択される、請求項32に記載の組成物。
- 保存剤が、総量の0.01%〜0.2%の重量濃度におけるソルビン酸カリウムである、請求項32または33に記載の組成物。
- 請求項1〜34のいずれか一項に記載の組成物の製造方法であって、
下記の連続工程:
−脂肪相を界面活性剤系と混合して、機械的攪拌により混合物を均質化し;
−異なる補助剤を水相で混合し;
−組成物の透明性を得られる速度で十分な時間にわたり、攪拌しながら水相を脂肪相へ配合し;
−必要に応じて、酸または塩基性溶液を加えることにより、エマルジョンのpHを調整し;
−室温で活性成分の完全溶解まで攪拌することにより、活性成分を配合する
ことを含んでなる、方法。 - 請求項1〜34のいずれか一項に記載の組成物を含んでなる、医薬組成物。
- 皮膚障害、頭皮および脂漏性皮膚炎を治療するための、請求項36に記載の医薬組成物。
- 請求項1〜34のいずれか一項に記載の組成物を含んでなる、化粧品。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0752901A FR2911781B1 (fr) | 2007-01-26 | 2007-01-26 | Emulsion dermatologique et procede de preparation |
| FR07/52901 | 2007-01-26 | ||
| PCT/EP2008/050879 WO2008095796A1 (fr) | 2007-01-26 | 2008-01-25 | Emulsion dermatologique et procede de preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010516743A JP2010516743A (ja) | 2010-05-20 |
| JP5313926B2 true JP5313926B2 (ja) | 2013-10-09 |
Family
ID=38655394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009546767A Expired - Fee Related JP5313926B2 (ja) | 2007-01-26 | 2008-01-25 | 皮膚用エマルジョンおよびその製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100068307A1 (ja) |
| EP (2) | EP2564831A1 (ja) |
| JP (1) | JP5313926B2 (ja) |
| AR (1) | AR065032A1 (ja) |
| CA (1) | CA2676232A1 (ja) |
| FR (1) | FR2911781B1 (ja) |
| WO (1) | WO2008095796A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20091075A1 (it) * | 2009-06-17 | 2010-12-17 | Valetudo Srl | Composizioni farmaceutiche e cosmetiche comprendenti lactoferrina ciclopirox acido etidronico |
| JP5548275B2 (ja) * | 2009-12-22 | 2014-07-16 | レオ ファーマ アクティーゼルスカブ | ビタミンd類似体および共溶媒−界面活性剤混合物から成る医薬品組成物 |
| US9254296B2 (en) | 2009-12-22 | 2016-02-09 | Leo Pharma A/S | Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture |
| US8933134B2 (en) | 2010-06-09 | 2015-01-13 | L'oreal | Compositions containing agar and a softening agent |
| JP6356382B2 (ja) * | 2012-12-21 | 2018-07-11 | ロレアル | 化粧品組成物 |
| WO2014134427A1 (en) * | 2013-02-28 | 2014-09-04 | Precision Dermatology, Inc. | Controlling the bioavailability of active ingredients in topical formulations |
| US10111956B2 (en) * | 2013-06-03 | 2018-10-30 | Tolmar, Inc. | Corticosteroid compositions |
| CN104523592B (zh) * | 2015-01-26 | 2017-03-15 | 湖北工业大学 | 甲泼尼龙醋酸酯注射用自微乳制剂及其制备方法 |
| KR102607078B1 (ko) * | 2016-08-10 | 2023-11-28 | 주식회사 엘지생활건강 | 오일을 고함유하는 세정제 조성물 |
| DE102016225873A1 (de) * | 2016-12-21 | 2018-06-21 | Henkel Ag & Co. Kgaa | Mittel und Verfahren zur temporären Verformung keratinhaltiger Fasern |
| JP2019014679A (ja) * | 2017-07-07 | 2019-01-31 | ロレアル | 超微細o/wエマルションの形態のケラチン繊維のためのシリコーン非含有組成物 |
| US11504327B1 (en) * | 2019-01-21 | 2022-11-22 | Eric Morrison | Method of preparing nanoparticles by hot-melt extrusion |
| CN111249221A (zh) * | 2020-02-28 | 2020-06-09 | 天津金耀药业有限公司 | 一种二氟可龙乳膏酯及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58186428A (ja) * | 1982-04-26 | 1983-10-31 | ザ・プロクタ−・エンド・ギヤンブル・カンパニ− | 起泡性界面活性剤組成物 |
| US4536318A (en) * | 1982-04-26 | 1985-08-20 | The Procter & Gamble Company | Foaming surfactant compositions |
| LU84515A1 (fr) | 1982-12-09 | 1984-10-22 | Oreal | Composition stable pour corticotherapie locale a forte concentration hydrocortisone solubilisee |
| ATE70446T1 (de) | 1988-01-13 | 1992-01-15 | Sanol Arznei Schwarz Gmbh | Konzentrierte corticosteroide enthaltende loesungen und verfahren zu deren herstellung. |
| GB9504265D0 (en) | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
| DE19509079A1 (de) | 1995-03-15 | 1996-09-19 | Beiersdorf Ag | Kosmetische oder dermatologische Mikroemulsionen |
| DE19641672A1 (de) * | 1996-10-10 | 1998-04-16 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen |
| US6075056A (en) * | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
| FR2820038B1 (fr) * | 2001-01-29 | 2004-07-02 | Dermaconcept Jmc | Composition dermatologique a usage veterinaire comprenant une base sphingoide |
| DE10149373A1 (de) * | 2001-10-06 | 2003-04-30 | Beiersdorf Ag | Antitranspirantprodukt auf Basis von Mikroemulsionsgelen |
| FR2850278B1 (fr) * | 2003-01-24 | 2005-02-25 | Gattefosse Ets Sa | Utilisation du 2-hydroxymethyltetrahydropyranne comme excipient dans une composition cosmetique ou pharmaceutique |
| US20050075407A1 (en) * | 2003-08-25 | 2005-04-07 | Foamix Ltd. | Foam incorporating eutetic mixture |
| US20060217283A1 (en) * | 2005-03-25 | 2006-09-28 | L'oreal | Foaming O/W emulsion and use thereof in cosmetics |
| FR2883475A1 (fr) * | 2005-03-25 | 2006-09-29 | Oreal | Emulsion h/e moussante et son utilisation dans le domaine cosmetique |
-
2007
- 2007-01-26 FR FR0752901A patent/FR2911781B1/fr not_active Expired - Fee Related
-
2008
- 2008-01-25 AR ARP080100309A patent/AR065032A1/es not_active Application Discontinuation
- 2008-01-25 US US12/523,263 patent/US20100068307A1/en not_active Abandoned
- 2008-01-25 CA CA002676232A patent/CA2676232A1/fr not_active Abandoned
- 2008-01-25 EP EP12170593A patent/EP2564831A1/fr not_active Withdrawn
- 2008-01-25 JP JP2009546767A patent/JP5313926B2/ja not_active Expired - Fee Related
- 2008-01-25 WO PCT/EP2008/050879 patent/WO2008095796A1/fr active Application Filing
- 2008-01-25 EP EP08701673A patent/EP2114373A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AR065032A1 (es) | 2009-05-13 |
| EP2114373A1 (fr) | 2009-11-11 |
| JP2010516743A (ja) | 2010-05-20 |
| WO2008095796A1 (fr) | 2008-08-14 |
| FR2911781A1 (fr) | 2008-08-01 |
| CA2676232A1 (fr) | 2008-08-14 |
| US20100068307A1 (en) | 2010-03-18 |
| FR2911781B1 (fr) | 2009-03-20 |
| EP2564831A1 (fr) | 2013-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5313926B2 (ja) | 皮膚用エマルジョンおよびその製造方法 | |
| CA3102689C (en) | Method and formulation for improving roflumilast skin penetration lag time | |
| KR20180024463A (ko) | 안정성이 우수한 수중유형 에멀젼 및 이를 포함하는 화장료 조성물 | |
| FR2750329A1 (fr) | Emulsion huile-dans-eau ultrafine gelifiee et stabilisee par un poly(acide 2 -acrylamido 2 -methylpropane sulfonique) reticule et neutralise a au moins 90 %, procede de preparation et applications | |
| BR112020024722A2 (pt) | composições tópicas para estimular crescimento capilar | |
| JP2023502539A (ja) | 高クラフト温度アニオン性界面活性剤を使用した皮膚症状の処置 | |
| JP6726498B2 (ja) | 外用組成物 | |
| ES2537553T3 (es) | Uso de pentilenglicol como solvente para hidrocortisona o derivados de la misma | |
| JP2012031125A (ja) | 紫外線吸収剤を含有する微細エマルション組成物並びに化粧料 | |
| JP2003040765A (ja) | W/o/w型複合エマルション | |
| JPH0899889A (ja) | アトピー性皮膚炎治療剤 | |
| JP2001163766A (ja) | 五環性トリテルペン酸を含む組成物、特に化粧品組成物 | |
| JPS5987035A (ja) | 尿素を安定に含むw/o型エマルジヨン組成物 | |
| JP6832059B2 (ja) | 乳化組成物 | |
| JP7570174B2 (ja) | 乳化安定化方法 | |
| JP2018193318A (ja) | 乳化組成物 | |
| Denei et al. | A Review on Formulation and Evaluation of Emulgel | |
| JP7709827B2 (ja) | 外用組成物 | |
| JP6084579B2 (ja) | タクロリムスを含有する水中油型クリーム状組成物 | |
| JP7512365B2 (ja) | 油性外用液 | |
| JPH08165244A (ja) | 皮膚疾患治療剤 | |
| JPS62225240A (ja) | 多価アルコ−ル中油型乳化組成物 | |
| JPH06183946A (ja) | 皮膚外用剤 | |
| WO2025197914A1 (ja) | 乳化型化粧料 | |
| JP5674786B2 (ja) | タクロリムスを含有する水中油型クリーム状組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110107 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130415 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130422 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130514 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130514 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130607 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130704 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |